Sonnet BioTherapeutics Holdings Inc. (NASDAQ:SONN) saw an upside of 7.10% to close Friday at $0.65 after adding $0.04 on the day. The 5-day average trading volume is 4,468,000 shares of the company’s common stock. It has gained $0.6500 in the past week and touched a new high 3 times within the past 5 days. An average of 6,741,355 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 12,395,016.
SONN’s 1-month performance is 1.11% or $0.0071 on its low of $0.5521 reached on 09/14/21. The company’s shares have touched a 52-week low of $0.55 and high of $3.41, with the stock’s rally to the 52-week high happening on 02/08/21. YTD, SONN has lost -70.90% or -$1.5810 and has reached a new high 12 times. However, the current price is down -81.00%% from the 52-week high price.
3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sonnet BioTherapeutics Holdings Inc. (SONN) has a trailing price-to-earnings (P/E) ratio of 33.83 for the broader industry and 32.48 for the sector, meaning that investors are optimistic about the stock’s future prospects.SONN stock has a beta of 0.67. Moving on to other valuation ratios, the price-to-book (PB) in the most recent quarter is 10.82.
Sonnet BioTherapeutics Holdings Inc.’s current ratio over the recent quarter at 1.20 meaning that SONN stock is able to fulfill its debt obligations. As well, the company’s long term debt to equity for the quarter ending June 29 was 0.00, while the total debt to equity was 0.00.
For the quarterly period ending June 29 this year, Net income and sales went up compared to those figures reported in the previous quarter. Analysts expected SONN to announce -$6.76 per share in earnings in its latest quarter, but it posted -$20.8, representing a -207.70% surprise. EBITDA for the quarter stood at more than -$6.22 million. SONN stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 5.81 million, with total debt at $0.15 million. Shareholders hold equity totaling $24.96 million
Let’s look briefly at Sonnet BioTherapeutics Holdings Inc. (SONN) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 01 October was 55.37% to suggest the stock is trending Neutral, with historical volatility in this time period at 49.67%.
The stock’s 5-day moving average is $0.6186, reflecting a +7.77% or $0.0468 change from its current price. SONN is currently trading -0.34% above its 20-day SMA, -58.13% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -43.57% and -74.75% respectively.
Stochastic %K and %D was 38.85% and 35.61% and the average true range (ATR) pointed at 0.0458. The RSI (14) points at 48.03%, while the 14-day stochastic is at 57.71% with the period’s ATR at 0.0597. The stock’s 9-day MACD Oscillator is pointing at 0.0071 and 0.0086 on the 14-day charts.
Analysts offering their rating for SONN stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate SONN as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 1 have offered a “buy” rating.
What is SONN’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $5.00 and a high of $5.00, with their median price target at $5.00. Looking at these predictions, the average price target given by analysts is for Sonnet BioTherapeutics Holdings Inc. (SONN) stock is $5.00.